April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Experimental CNV in Cynomolgus Monkeys after Sustained Release of VEGF and bFGF within the Suprachoroidal Space: Part 2. Natural History
Author Affiliations & Notes
  • Corinne G. Wong
    Ophthalmic Drug Dev, SCLERA LLC, Carlsbad, California
  • Ton Lin
    Biological Sciences, Allergan Inc, Irvine, California
  • Yong Li
    Biological Sciences, Allergan Inc, Irvine, California
  • James Burke
    Biological Sciences, Allergan Inc, Irvine, California
  • Timothy You
    Ophthalmic Drug Dev, RETINA, Irvine, California
  • Larry Wheeler
    Biological Sciences, Allergan Inc, Irvine, California
  • Corine Ghosn
    Biological Sciences, Allergan Inc, Irvine, California
  • Footnotes
    Commercial Relationships  Corinne G. Wong, None; Ton Lin, Allergan (E); Yong Li, Allergan (E); James Burke, Allergan (E); Timothy You, None; Larry Wheeler, Allergan (E); Corine Ghosn, Allergan (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4000. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Corinne G. Wong, Ton Lin, Yong Li, James Burke, Timothy You, Larry Wheeler, Corine Ghosn; Experimental CNV in Cynomolgus Monkeys after Sustained Release of VEGF and bFGF within the Suprachoroidal Space: Part 2. Natural History. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4000.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The goal of this study was to follow the natural history of experimental monkey CNV after suprachoroidal sustained release of both VEGF and bFGF. Part 2. Natural History of Experimental CNV in Non-Human Primates.

Methods: : In this pilot monkey study (N = 5), either non-biodegradable placebos or VEGF/bFGF implants that are shown to produce in the rabbit progressive CNV after suprachoroidal implantation (Zahn et al.), were used. One monkey eye initially was implanted with the VEGF/bFGF pellet to establish the procedure and define preliminary histology. In the other monkeys (N=4) subsequent implants, 1x or 2x VEGF/bFGF in the OD eyes or placebo in the OS eyes, were placed suprachoroidally, within 2 disc diameters of the macula. One day post implant, with a Kryptom-red laser, 3 spots were placed on retinas next to each pellet. In the following 14 wks, all monkeys were anesthetized and monitored with color fundus photography, fluorescein angiography, multifocal ERG, and spectral domain OCT. At either wk 7 or wk 14, eyes were enucleated and then placed in neutral buffered formalin for several days. Following dissection, areas containing the macula, laser burns, and VEGF/bFGF implants were processed and embedded into paraffin for appropriate serial dissection and then stained with hematoxylin and eosin.

Results: : Fluorescein leakage was seen around the laser spots and above the implants in all eyes that had VEGF/bFGF implants from wk 1 up to wk 14 with varying intensities. Fluorescein leakage was not observed in placebo-implanted eyes. In 2 eyes, the florid leak peaked at wk 8 and included vessel tortuosity. In the other 2 eyes, leakage was less and the pattern was reminiscent of plypoidal choroidal vasculopathy. In OD eyes, at both 100X and 200X, dilated blood vessels by the VEGF/bFGF implant could be seen in the choroidal layer not far from the macula. Laser burns demonstrated severe disruption of both retina and choroid. Normal-appearing maculas were found in all OS eyes.

Conclusions: : Experimental intra-CNV can be induced in the non-human primate eye through a VEGF/bFGF implant within the suprachoroidal space.

Keywords: choroid: neovascularization • retinal neovascularization • choroid 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×